In this review, we highlight experiments conducted in our laboratories that have eluci- 
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FOSTER ET al. cell infiltrate profiles and immune cell activation patterns. This has led to the description of four subtypes of asthma, including allergic/ eosinophilic, neutrophilic, mixed eosinophilic/neutrophilic, and paucigranulocytic. Furthermore, individual disease severity can range from mild to severe. While steroids (primarily inhaled glucocorticoids) and bronchodilators (β-adrenergic receptor agonists) remain as mainstay therapy for most asthma patients, responsiveness to these agents often depends on the phenotype and severity of disease. Thus, while the majority of individuals with mild-to-moderate allergic/eosinophilic asthma achieve control of their symptoms through standard treatment with steroids and bronchodilators, patients with other subtypes or severe disease can be resistant to these therapies. These (above) subjects are covered in substantial detail in several excellent recent reviews. [1] [2] [3] [4] [5] Controlling exacerbations of asthma remains difficult. Exacerbations are commonly induced by infection further exacerbated by secondary infections as well as allergens and are a major cause of hospitalization, especially in children. Further, exacerbations account for a large proportion of the healthcare costs associated with asthma management (reviewed in 6 ). Those at greatest risk have more severe airway disease and poor symptom control (termed steroid-resistant or treatmentrefractory asthma). However, exacerbations can also afflict patients whose disease is typically well controlled by steroid therapy. In addition, It is important to recognize that current therapies only treat asthma symptoms and not the underlying cause of disease. Furthermore, it is equally crucial to recognize that a significant proportion of individuals suffer from severe disease, and remain symptomatic despite medication use. 7 The challenge for the future is to develop tools that can easily classify patients into specific subtypes, to facilitate treatments with appropriate disease-modifying therapeutics. However, the development of targeted, rational treatment approaches for asthma requires a thorough understanding of disease mechanisms. The development of these approaches requires coordination between clinical, translational, and basic research studies to identify important disease targets in appropriate models of disease pathogenesis.
An important example of this approach is the examination of the T H 2 paradigm, specifically recognition of the role of dysregulated T H 2 immune responses in mediating disease. This recognition encompasses the initial discovery in mice of distinct T H 1 and T H 2 subsets; the association of T H 2 cells, the cytokines they secrete (e.g. interleukin-
[IL]-5), and pathways they operate (e.g. IgE production and eosinophil development) with asthma pathogenesis; modeling the role of T H 2 cell-regulated pathways in animal models; and the implementation of clinical trials targeting candidate cytokines and molecules.
In this review, we were invited to highlight experiments conducted primarily in our laboratories (in conjunction with many collaborators) that have focused on understanding the fundamental pathways underpinning the pathogenesis of asthma by employing a range of mouse models (see [8] [9] [10] [11] [12] [13] [14] for excellent reviews with broader field focus).
In the development of these models, we have utilized the clinical data of the "time" to shape the development of appropriate models to gain insights into pathogenic mechanisms. These include models of acute T H 2-driven allergic airway disease (AAD), eosinophil expansion, migration and homing, chronic disease, steroid-resistant inflammation, and disease exacerbations induced by a range of triggers.
In particular, we will focus on early investigations that dissected the role of allergen-specific T H 2 cells and associated cytokines/ chemokines, together with the role of eosinophils in driving hallmark clinical features of allergic asthma. We also describe our investigations into the molecular and cellular processes regulating the development of T H 2 cells, chronic asthma, steroid-resistant inflammation, and asthmatic exacerbations. Although the T H 2 paradigm may have temporarily polarized experimentation in the field toward a single hypothesis, collectively, its examination by many investigators led to the realization that other inflammatory phenotypes existed in asthma and the recognition of more multifaceted triggers of disease (e.g. infection).
We propose that understanding the diversity and spatiotemporal role of inflammation and its interactions with resident airway cells will be crucial to advancing knowledge on asthma pathogenesis and the development of new therapeutic approaches.
| MODELING THE ROLE OF T H CELLS, ASSOCIATED CYTOKINES, AND CCL11 IN THE REGULATION OF ALLERGIC AIRWAY DISEASE

| Role of T H 2 cells and IL-4, IL-5, and IL-13
At the beginning of our investigations into the pathophysiology of asthma (in early 1992), asthma was understood as a chronic disease of the airways, characterized clinically by reversible airway obstruction, enhanced bronchial responsiveness to spasmogens (also known as AHR), and airway inflammation. The underlying inflammatory response was thought to play a critical role in the development and progression of disease and the induction of AHR. This included a role in altering the structural integrity of the epithelium and in remodeling of the airway wall. Notably, at this time, the cellular composition of inflammatory infiltrates into the lung was recognized to be diverse; lung infiltrates included activated neutrophils, mast cells, eosinophils, and monocytes/macrophages. The recruitment and/or activation of these cells was thought to be controlled by the secretion of cytokines and chemotactic factors released from antigen-stimulated T lymphocytes and other structural (e.g. epithelial) and inflammatory cells (e.g. dendritic cells). [15] [16] [17] [18] [19] [20] At this time, the concept of distinct inflammatory phenotypes of asthma had not yet emerged and there was increasing interest in the involvement of eosinophils and factors secreted from T H 2 cells in disease pathogenesis. 16, 17, [19] [20] [21] [22] [23] This largely stemmed from a rapidly emerging body of clinical studies where eosinophil accumulation in the airways was a predominant feature of the inflammatory infiltrate, which often correlated with disease severity. 15, 18, 24, 25 Furthermore, increased numbers of activated T H 2 cells and levels of the eosinophilspecific regulatory cytokine, interleukin-5 (IL-5), had been observed in the lungs of asthmatic patients and after experimental allergeninduced late-phase reactions. 16, 17, 19, 20, 26 Airway narrowing and disease progression through tissue damage were directly attributed to eosinophil activation and the release of cationic granule proteins into the airways. 21, 27, 28 Roles for other T H 2 cytokines remained largely unknown; while IL-4 was linked to the regulation of type-2 immune responses and IgE production, the role of IL-13 had not been explored.
| Role of IL-5 and eosinophils
To gain some insight into the role of IL-5 and eosinophils in regulating asthmatic responses, we employed IL-5 gene-deleted mice (Il5 −/− mice) 29, 30 in conjunction with models of acute T H 2-mediated allergic inflammation. For our studies, we employed a classic model of AAD induced by sensitization and aeroallergen challenge with the archetypal type-2 antigen ovalbumin (OVA). 30 This model allowed the direct dissection of T H 2 cells and secreted cytokines in the mechanism leading to pathogenic features of allergic eosinophilic asthma and significantly advanced our understanding of the role of this pathway in disease. Furthermore, they built on earlier studies highlighting the potential role of IL-5 and eosinophils in the pathogenesis of asthma. 26, 29, [31] [32] [33] [34] [35] Sensitization and aeroallergen challenge of wildtype C57Bl/6 mice with OVA induced AAD and hallmark features of asthma, including the development of antigen-specific T H 2 cells, eosinophilia, eosinophil accumulation in the lung, mucus hypersecretion, epithelial cell shedding, and occlusion of the airways. 30 These inflammatory and pathophysiological changes correlated with the development of AHR in response to administered methacholine, a spasmogen that is also used as a clinical tool to assess airway responses in asthmatic patients. 30 Notably, Il5 −/− C57Bl/6 mice, in the absence of eosinophils, were protected from all features of AAD. 30 Interestingly, allergic sensitization was unaffected, with no difference in circulating levels of allergenspecific IgE. 30 Further, reconstitution of IL-5 production (by delivery of vaccinia virus expressing IL-5 to the lung) completely restored all features of disease. 30 Of note, earlier studies that featured monoclonal antibodies (mAbs) targeting IL-5 had been shown to suppress, but not abolish, pulmonary eosinophil accumulation in response to antigen challenge, and the correlation of this effect with changes in lung morphology and AHR was controversial. 32, 34 Our study, utilizing mice fully devoid of IL-5, clearly demonstrated the central importance of this cytokine in inducing eosinophilia and subsequent lung damage and inflammation in response to T H 2-inducing antigens.
In a subsequent study, we extended these findings and demonstrated that treatment with an anti-IL-5 mAb before allergen challenge could profoundly suppress eosinophil recruitment to the peripheral blood and airways, lung damage, and reduce the magnitude of AHR. 36 The central importance of IL-5 derived from T H 2 cells for the development of eosinophilia and allergic inflammation was also demonstrated. 37 The transfer of primed OVA-specific CD4 + T H 2 cells from OVA-sensitized wildtype mice into OVA-sensitized Il5 −/− mice was sufficient to restore blood and airway eosinophil numbers, lung damage, and AHR after antigen challenge. 37 
| Role of IL-4 and IgE
We next investigated the roles of IL-4 and IgE in the regulation of AAD. [38] [39] [40] [41] Both of these molecules have been implicated as central mediators of asthma. At the time, IL-4 was thought to be a critical factor in the regulation of T-cell commitment to the T H 2 phenotype, based on studies of T-cell differentiation carried out in vitro, and considered to play an essential role in IgE isotype-switching in B cells. 38, [42] [43] [44] IL-4 also had potential roles in the maintenance of the inflammatory response to recall antigens and regulating production of the eosinophil-specific chemoattractant CCL11. 38, 39, 45 IgE had been identified as a key factor for the activation of mast cells, and there was emerging evidence that it played a role in the regulation of eosinophilmediated AHR by modulation of T H 2 cell function via B cells. 35 To ascertain the roles of IL-4 and IgE in disease processes, we employed our model of acute AAD and evaluated mice deficient in IL-4 and CD40 (on a mixed 129Sv X C57BL/6 background). In Il4
mice following induction of allergic inflammation, we observed a reduction in the numbers of eosinophils recruited into the airways and decreased levels of antigen-specific IgE and IgG1. 46 However, tissue damage and AHR were not affected and antigen-specific IgG2a and IgG3 were detected. 46 Further, treatment of Il4 −/− mice with anti-IL-5 reduced blood and airway eosinophil recruitment and AHR. 46 Next, we used CD40 −/− mice in the aeroallergen-induced AAD model.
CD40
−/− mice exhibit impaired T-cell-dependent immunoglobulin class switching and germinal center formation. 47 Aeroallergen challenge of sensitized CD40 −/− mice resulted in a severe inflammatory response, characterized by elevated numbers of blood and BALF eosinophils, mucous hypersecretion, and AHR. was targeted during the initial sensitization phase (but not effector phase). 48 Pretreatment with anti-IL-5 mAb during the sensitization phase had also been shown to inhibit airway eosinophilia, but not AHR. 48 Our work demonstrated that IL-5 was also required for AHR Gros and colleagues. 55, 56 This observation also highlighted that critical factors identified in T-cell polarization assays in vitro may not be essential in the dynamic living system.
| Variations in mouse strains can influence the role of T H 2 factors in the development of allergic inflammation
One difference between the elegant work of Corry et al. (which demonstrated a role for IL-4 but not IL-5) and our studies was the use of different strains of mice. Corry et al. 48 used BALB/c mice, whereas we primarily employed C57Bl/6 mice. Although pronounced and reproducible T H 2 responses can be induced by sensitization and challenge of the C57Bl/6 strain, BALB/c mice were thought to be innately more "T H 2-like"/prone. Therefore, the relative contribution of the IL-4/ IgE and IL-5/eosinophil pathways to the induction of AAD in different strains of mice may account for the differences observed in these studies. 57 To explore this possibility, we utilized Il4 −/− and Il5 −/− mice backcrossed onto the BALB/c strain in combination with inhibitory mAbs to these cytokines, to identify the contribution of these factors to the induction of allergic inflammation and AHR. 58 Inhibition of the actions of IL-4 and/or IL-5 in mice on a BALB/c genetic background did not abolish AHR. 58 63, 64, 69 This eosinophilic response was dependent on CCL11 and STAT6 and suggested that while IL-5 can operate as a cofactor with CCL11 to induce eosinophil recruitment to tissues, it can also operate independently of this cytokine. 69, 86 These investigations also highlighted the broad proinflammatory activity of IL-13, which could critically activate a range of immune pathways that linked innate and adaptive immunity. These observations are currently very relevant to how IL-
13-or IL-5-producing ILC2s may exaggerate innate immune responses
during infection-induced exacerbation of asthma. Furthermore, we had demonstrated unique cooperative interactions between IL-5 and CCL11 for the regulation of blood and tissue eosinophils (see section below for a detailed description of this relationship). Subsequent investigations by others identified two more eotaxin family members CCL-24 (eotaxin-2) and CCL-26 (eotaxin-3, which is exclusively human), which also acted to specifically recruit eosinophils into tissue.
However, these molecules had different temporal contributions to the phases of recruitment. [87] [88] [89] To further explore the unique nature of the IL-5/IL-13/CCL11 axis and its role in the regulation of eosinophil migration and the development of allergic inflammation and AHR, we generated BALB/c mice deficient in both IL-5 and CCL11 (Il-5
). 74 In Il-5
mice, eosinophil accumulation was totally abolished in the lung after aeroallergen challenge, providing evidence that the accumulation of tissue eosinophils observed in Il5 −/− mice was regulated by CCL11. 74 The absence of eosinophils correlated with inhibition of AHR. 74 Further, we determined that eosinophils may be contributing to the development of AHR by regulating the production of T H 2-derived IL-13. mice restored the ability of their T H 2 cells to produce IL-13. 74 Thus, in the absence of eosinophils, T H 2 cells had an intrinsic defect in their ability to produce IL-13, and this was directly correlated with the number of eosinophils in the microenvironment. In further experiments, we showed that IL-13 production from CD4 + T cells taken from IL-5 overexpressing transgenic mice was significantly greater than from wildtype T cells. 74 Further, the level of T H 2-derived IL-13 and IL-13 in peribronchial lymph nodes directly correlated with the development and degree of AHR. 74 We also indirectly demonstrated a potential role for IL-18 derived from eosinophils as the factor regulating IL-13 production. 74 This study demonstrated bidirectional signaling between eosinophils and T H 2 cells in the regulation of allergic disease and high- We and others went on to demonstrate that eosinophils could act as antigen-presenting cells and directly promote allergic inflammation by activating T H 2 cells in an antigen-specific manner. [91] [92] [93] [94] After aeroallergen challenge of sensitized mice, eosinophils rapidly trafficked to the lung and then to sites of antigen presentation, including the lung-draining lymph nodes. 94 Eosinophils expressed MHCII and the costimulatory molecules CD80/86 and could internalize and present antigen. 94 Further, antigen-loaded eosinophils could promote the production of IL-4/-5/-13 from antigen-specific T H 2 cells and could prime for allergic inflammation upon transfer to naive animals. 94 
| DEFINING THE RELATIONSHIP BETWEEN IL-5 AND CCL11 FOR THE REGULATION OF EOSINOPHIL MIGRATION
Although we had demonstrated a critical role for IL-5 in the expansion of eosinophils in the bone marrow and induction of eosinophilia during allergic inflammation (supporting previous studies of parasitic infestation 49 ), the critical signal for eosinophil-specific homing to tissue remained unknown. At the time of our initial investigations into the role of IL-5 in the regulation of allergic inflammation, the eosinophilspecific chemoattractant CCL11 was discovered and cloned. 45, 80, [96] [97] [98] This was exciting, as this molecule appeared to be the critical homing signal for eosinophils. We designed fundamental experiments to determine the relationship between IL-5 and CCL11 for the regulation of eosinophil migration.
Systemic intravenous (i.v.) administration of recombinant IL-5 or CCL11 into wildtype mice induced a rapid eosinophilia, while CCL11 administration could also induce eosinophilia in Il5 −/− mice. 86 These studies highlighted a role for IL-5 in the mobilization of bone marrow eosinophils and CCL11 in the recruitment of eosinophils from tissues into the blood. 86 Further, pretreatment of Il5 −/− mice with IL-5 was necessary to promote eosinophil homing and tissue accumulation in response to CCL11, highlighting cooperative roles shared between IL-5 and CCL11 in eosinophil activation and migration. 86 Interestingly, although i.v. CCL11 induced eosinophilia in wildtype mice, this did not correlate with a significant reduction in the level of bone marrow eosinophils. 86 By contrast, i.v. IL-5 administration resulted in depletion of the bone marrow store of eosinophils in wildtype mice. 86 These results suggest the existence of two mechanisms by which eosinophilia can be rapidly induced. One mechanism occurs through expansion and mobilization of an IL-5-dependent bone marrow pool, while the second involves the mobilization of eosinophils from tissues into the circulation by eosinophil-specific chemoattractants, such as CCL11. Interestingly, the fact that CCL11 could direct eosinophils into systemic circulation suggests the existence of a pool of eosinophils located in tissues other than the bone marrow, which could be rapidly mobilized independently of IL-5 stimulation (this population would be mature effector cells). Furthermore, this pool of eosinophils, which is recruited to the lung in the absence of IL-5, then contributed to AAD. Tissue-resident eosinophils are found at many sites in the body (e.g. gastrointestinal tract, adipose tissue, thymus, uterus, lung, and mammary glands) where they have been proposed to play important biological roles. 85 Recently, Mesnil et al. 99 have also proposed that resident pulmonary eosinophils may contribute to homeostatic immune processes. They report resident pulmonary parenchymal eosinophils (rEOS) at steady state, which are described as IL-5-independent Siglec-
lo cells. 99 During induction of AAD, the phenotype of rEOS does not change, and mice deficient in these cells showed enhanced T H 2 cell responses to inhaled allergens. 99 The regulatory role of rEOS was linked to their ability to inhibit DC maturation and attenuate T H 2 responses. 99 We would speculate that the IL-5 independent pool of eosinophils observed in our studies during allergic inflammation are recruited to the lung from other tissues and do not represent steady-state rEOS. 99 To model tissue recruitment, we next injected recombinant CCL11
and/or IL-5 subcutaneously into the skin. 86 When injected into this tis- immune responses and eosinophil degranulation. 102 The interaction of T H 2 cytokines and CCL11 for the regulation of bone marrow, blood, and tissue eosinophilia is reviewed in. 73, 85, 103 We also demonstrated cooperative signaling between CCL24 and IL-5 for the recruitment of eosinophils into the lung. 104 Findings in this investigation establish the potential importance of CCL24 in the induction of key phenotypic characteristics of experimental asthma and assisted in clarifying the link between eosinophils and IL-13 for the induction of AHR.
| ANTI-IGE AND T H 2 CYTOKINE THERAPIES: EARLY FAILURES AND LONG-TERM SUCCESS
Collective investigations by many groups looking at the role of T H 2 cells and the cytokines IL-4, IL-5, IL-13, and IgE in asthma pathogenesis lead to clinical trials. In initial clinical trials, humanized anti-IL-5 (mepolizumab) treatment decreased blood eosinophil numbers and reduced blood and sputum eosinophils after allergen challenge. 78 However, treatment had no effect on AHR or late-phase allergic responses. 78 A second study of patients with poorly controlled asthma demonstrated that treatment effectively decreased blood and sputum eosinophil levels, but did not provide significant improvements in symptoms, quality of life, or exacerbation frequency. 105 These trials recruited patients based on asthma severity, rather than assessing underlying drivers of disease pathogenesis. The poor results that were obtained caused a severe setback to the field. However, the numbers of eosinophils remaining in lung tissue after treatment with mepolizumab may have been a confounding factor limiting therapeutic benefit, based on data from IL-5-deficient mice and anti-IL-5 mAb-treated models of AAD. 58, 73, 74, 79 It was not until follow-up studies were conducted, in which participants were selected based on the level of eosinophils detected in sputum samples (≥3% eosinophils in sputum) that clinical benefit was successfully and clearly demonstrated. In these studies, anti-IL-5 treatment was shown to reduce sputum and blood eosinophils and also improve asthma control and lung function and reduce corticosteroid dose. 77 In other words, when patients were selected based on the presence of eosinophilic inflammation and recurrent exacerbations, treatment reduced exacerbation frequency. 75 107 These patients had evidence of IL-13-regulated biological activity as measured by increased circulating levels of periostin. Notably, the higher the serum periostin levels, the greater the therapeutic benefit. 107 Clinical trial findings of an antibody targeting IL-4Rα (dupilumab) were also recently reported to improve lung function and reduce exacerbations in patients with uncontrolled persistent asthma. 108 Further studies on the IL-13/ IL-4Rα axis for treatment are required.
Overall, these clinical studies provide confirmation that type-2 inflammation underlies the pathological changes of allergic asthma, and they highlight the importance of disease heterogeneity even within this disease subtype. However, no treatment options are available that focus on disease onset, and there are limited options for individuals with non-allergic phenotypes, as well as for the treatment of severe, acute exacerbations of disease.
| UNDERSTANDING FACTORS THAT INITIATE AND REGULATE T H 2-INDUCED ALLERGIC INFLAMMATION
The 
| Role of IL-25 in allergic inflammation
Epithelial cell production of IL-25 plays an important role promoting T H 2 responses, in part by promoting the development of ILC2s. 117, 118 In one of the earlier studies that demonstrated a role for IL-25 in allergic inflammation, we showed that administration of IL-25 to the lungs of naive mice induced AHR, eosinophilic inflammation, mucus ).
ILC2s can induce allergic inflammation, mucous hypersecretion, and AHR. 126 Interestingly, concurrent studies in our laboratory demonstrated that arginase-I expression in the lung is induced by IL-13 and inhibition of its activity by RNA interference (RNAi) treatment of the airways attenuated IL-13-induced AHR. 127 Arginase-I had also been identified as a potential critical regulatory factor of disease in several models of experimental asthma. 
| The role of the epithelium in regulating T H 2 type responses in asthma
In a series of experiments with Joerg Mattes and colleagues (The University of Newcastle, Australia), we identified new pathways in airway epithelial cells that play central roles in the development of the T H 2 response. In particular, our work has highlighted a role for tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and midline 1 (MID1, also known as tripartite motif-containing protein (TRIM) 18) in the development of type-2 inflammation and AHR. [130] [131] [132] [133] [134] TRAIL is a member of the TNF superfamily of cytokines, 135, 136 which have essential roles in the regulation of immune and inflammatory responses (reviewed in 137 ). We were particularly interested in this molecule, as its expression was increased in the airway epithelium of asthmatics and increased further during the allergen-induced latephase response in asthma, correlating with inflammation and a decline in lung function. 138 Further, TRAIL was also expressed in immune cells linked to asthma pathogenesis (e.g. human T H 2 cell clones, eosinophils, neutrophils, and dendritic cells). [138] [139] [140] In our first study, we demonstrated that TRAIL is abundantly expressed in the airway epithelium of aeroallergen-challenged mice and is increased in sputum from individuals with asthma. 130 In 2009, we published a paper describing, for the first time, the role of miRNA in regulating allergic inflammation. 151 At the time, we were interested in miRNA function because regulation of miRNA expression had been linked to TLR signaling. [152] [153] [154] As mentioned above, we had identified an important role for TLR4 in the initiation of HDMinduced allergic disease. 142 This suggested that a potential link may exist between the innate immune system and subsequent activation of inflammatory pathways and adaptive immunity, via miRNA function.
Moreover, we wanted to assess the effect of targeting a miRNA linked to allergic inflammation, as a potential novel, broad anti-inflammatory approach. This approach seemed interesting as a single miR can target hundreds of mRNAs and modulate protein output from their respective genes. 144 Therefore, a single or specific set of miRNAs may control discrete physiological processes by regulating the production of a few critical proteins that coordinate single or interrelated cellular events (e.g. cell proliferation, or in our case coordinated inflammation).
144,146
| Role of miR-126
To assess potential functional roles of miRNAs in the regulation of 149, 150 ).
The effect of blocking miR-126 function was less dramatic in a mouse model of chronic asthma, where allergic inflammation was induced by low-level exposure of the airways to OVA for 6 weeks. (unlike the HDM model).
| Role of miR-145
In a subsequent study, we also assessed the effects of antagomir treatment against miR-145, miR-21 and miR-let-7b in a HDM-induced model of AHR. 156 Of these interventions, only ant-miR-145 treatment could suppress features of disease. 156 Treatment reduced eosinophilic inflammation, mucus hypersecretion, T H 2 cytokine production (IL-5 and IL-13), and AHR. 156 Inhibition of all disease features was similar to corticosteroid treatment alone. 156 Interestingly, miR-145 has also been linked to the regulation of innate immunity by inhibiting IFNβ production, 157 and is one of the highly expressed miRs within the trachea and airway wall. 158 Smooth muscle development and the differentiation of fibroblasts into smooth muscle cells have also been We have also assessed the role of miRNAs in antimicrobial defense, with relevance to exacerbation of respiratory disease such as asthma and obstructive pulmonary disease (COPD). We demonstrated that miR-328 is reduced in neutrophils and macrophages, upon exposure to non-typeable Haemophilus influenzae in vitro. 161 Antagomirmediated inhibition of miR-328 enhanced bacterial killing, both in vivo and in vitro, without increasing inflammatory cytokine production. 161 Importantly, ant-miR-328 treatment also improved bacterial clearance under conditions of corticosteroid-induced immunosuppression and in a model of chronic COPD. 161 These findings provide a potential approach for the treatment of bacterial infections and/or exacerbations in respiratory disease such as asthma and COPD.
| miRNA expression in inflammatory cell populations relevant to asthma
We have also undertaken a number of studies to determine the role of miRNAs in the differentiation, proliferation, and activation of immune cells relevant to respiratory disease. In our first study, we identified 86 miRNAs with altered expression during the in vitro differentiation of bone marrow-derived mast cells. 162 Target prediction analysis identified subsets of altered miRNAs with potential roles regulating key mast cell surface receptors, transcription factors, signaling molecules, and secretory proteins. 162 For example, in silico analysis predicted seven specific miRNAs which are directly associated with the expression of the mast cell surface receptors c-Kit and the high affinity IgE receptor (FcεRIα). 162 A further 18 miRNAs promote expression of MITF, GATA-1, and c/EBPα, three core transcription factors that direct mast cell differentiation. 162 Furthermore, we identified 11 miRNAs that may regulate the expression of STAT-3,
STAT-5a/b, GATA-2, and GATA-3 during differentiation, along with 13 miRNAs that target transcripts encoding Ndst2, mast cell protease 4 (mMCP4) and mMCP6, and thus may regulate biosynthesis of mast cell secretory mediators. 162 In a similar approach, we identified 68 miRNAs that are changed during in vitro differentiation of eosinophils. 163 Again by employing TargetScan and MeSH databases, we identified 348 transcripts involved in 30 canonical pathways that are potentially regulated by these miRNAs. 163 Networks of miRNAs appear to target key eosinophil surface molecules and transcription factors, as well as potential regulation of TLR-4/13 expression. 163 For example, 13 specific miRNAs were temporally associated with the expression of IL-5Rα and the CCL11 receptor CCR3 and 14 miRNAs were associated with regulation of the transcription factors GATA-1/2, PU.1 and C/EBPε. A further 17 miRNAs may regulate translation of TLR-4/13.
We also assessed miRNA expression profiles during differentiation of bone marrow-derived macrophages. We identified 112 miRNAs with altered expression. 164 Employing network analysis databases, we identified 1267 transcripts involved in 30 canonical pathways linked to macrophage biology as potentially regulated by these specific 112 miRNAs. 164 Eighteen miRNAs were temporally linked to the expression of CSF1R, CD36, MSR1, and SCARB1; seven miRNAs linked to the regulation of the macrophage transcription factors RUNX1 and PU.1; and 14 miRNAs predicted to target the nuclear receptors PPARα and PPARγ. 164 These are all factors linked to the development and activation of macrophages. Notably, miR-328 was highly upregulated by day 7 of differentiation and we have demonstrated its importance in regulating the proinflammatory status of macrophages (as discussed above 161 ).
These are some of the first investigations to map changes in miRNA expression in whole bone marrow cultures during the differentiation of mast cells, eosinophils, and macrophages. They provide evidence of potential functional links between miRNA expression and their target mRNAs for the regulation of differentiation, cellular identity, and function. Identification of the specific miRNA subsets employed in these processes offers potential avenues to attenuate the expansion and function of these immune cell populations at sites of inflammatory disease.
As an example, we extended these studies and have started to examine the functional relevance of the identified miRNAs in the regulation of macrophage differentiation and/or function. 165 In this regard, we identified key roles for miR-487b as a negative regulator of macrophage activation. 165 MiR-487b was increased during macrophage differentiation, and we demonstrated that it directly binds to IL-33 mRNA, inhibiting IL-33 production in macrophages. 165 IL-33 is known to play an important role in macrophage activation for innate host defense and proinflammatory responses. For example, IL-33 regulates macrophage foam cell formation, promotes the polarization of alternatively activated macrophages, and can enhance macrophageregulated antibacterial immunity. [166] [167] [168] In this study, exposure of macrophages to IL-33 increased MHC I/II, CD80/86, and iNOS expression and inhibition of miR-487b function promoted these responses. 165 Stimulation with LPS to activate macrophage proinflammatory pathways suppressed miR-487b expression and increased expression of IL-33 and proinflammatory mediators (e.g. iNOS, IL-1β, IL-6, and TNFα). 165 Ant-miR-487b administration also increased IL-33 expression and enhanced LPS-mediated induction of inflammatory gene expression. 165 Collectively, our results indicate that miR-487b plays a negative regulatory role in macrophages, by controlling the levels of IL-33 transcript and protein to fine-tune innate immune host defense and proinflammatory responses of these cells.
| MODELING CHRONIC ASTHMA
A major focus in a long-term collaboration with Rakesh Kumar (University of New South Wales, Australia) was aimed at understanding the development of inflammation and lesions (remodeling) in chronic asthma by employing a chronic antigen exposure model. Here, we highlight some of our investigations, which identify the complexity of the mechanisms leading to chronic disease, steroid-insensitivity, and disease exacerbation. Interestingly, when we examined potential therapeutic interventions in this model, we often demonstrated dissociation between inflammation, tissue remodeling, and AHR and identified contributions of non-T H 2-type responses to pathogenesis.
By contrast to our acute exposure models, in chronic models, mice were sensitized and chronically challenged (6-8 weeks) with low concentrations of aerosolized OVA. 169 Repeated OVA exposures caused low-grade airway-specific inflammation, with intraepithelial eosinophils, lymphoid, and mononuclear cells within the lamina propria, goblet cell hyperplasia, features of tissue remodeling (epithelial thickening and subepithelial fibrosis), and increased levels of IgE. 169 Further, chronic OVA exposure induced AHR. 169 In later studies (using Flexivent technology), we were able to demonstrate that AHR induced in response to methacholine exposure in this model was also airwayspecific (as in asthma) and not derived from other lung compartments.
Further, in contrast to acute models and other published models of This model of chronic asthma was subsequently used to define many novel aspects of pathogenesis. For example, we investigated the contribution of T H 2 cytokine-driven inflammation to the development of airway lesions and AHR by employing cytokine-deficient mice and assessed the effects of chronic (6-week) exposure of OVA on chronic inflammation and epithelial changes. 170 In Il5 −/− mice, eosinophil numbers were decreased, but epithelial hypertrophy and subepithelial fibrosis were unaltered. 170 However, Il5 −/− mice were protected from the development of AHR. 170 In contrast, Il4 −/− mice had significantly more epithelial hypertrophy and subepithelial fibrosis and increased AHR, while airway inflammation was unaltered. 170 Thus, we concluded that IL-5, but not IL- The dissociation between airway wall remodeling and AHR has important implications for therapeutic approaches to asthma.
We also highlighted a key role for CD4 + T cells in the chronic challenge model. 171 Depletion of CD4 + T cells decreased AHR and reduced features of airway remodeling (including subepithelial fibrosis, epithelial thickening, and mucus cell hyperplasia). 171 Chronic inflammation was also reduced, with reduced accumulation of Ig-producing plasma cells. 171 However, eosinophil accumulation and CCL11 expression were unaffected. 171 These findings provided evidence for an import- 173 have demonstrated plasma cells and eosinophils colocalize together in the bone marrow. Eosinophils were shown to provide key survival factors for plasma cells. 173 In the absence of eosinophils, the numbers of plasma cells were much lower in the bone marrow both at steady state and after immunization. 173 Based on our studies in the lung, we speculate that eotaxin produced by plasma cells may play a key role in this spatial arrangement.
We extended these studies on the role of T H 2 cytokines and fac- In further investigations, we examined the therapeutic potential of phosphodiesterase inhibitors for the treatment of chronic asthma.
We compared the effects of roflumilast (PDE4 inhibitor) or pentoxifylline (non-selective phosphodiesterase inhibitor) with steroid treatment (dexamethasone). Both roflumilast and dexamethasone inhibited eosinophil accumulation, inflammation, subepithelial collagen deposition, and epithelial thickening and had minor effects on the level of AHR. 176 Dexamethasone also reduced goblet cell hyperplasia, TGFβ1 levels and activation of NFκB in the epithelium. 176 By contrast, pentoxifylline only inhibited eosinophil accumulation and epithelial thickening, but also significantly reduced AHR. 176 The differences observed between pentoxifylline and roflumilast treatment might be attributed to the more effective inhibition of NFκB signaling by non-specific PDE inhibitors (pentoxifylline), than by PDE4-specific agents (roflumilast).
Collectively, the above observations led us to look into the interplay between T H 2 (e.g. IL-13, IL-5) and T H 1-associated factors (IFNγ) and other inflammatory molecules (e.g. TGFβ1 and amphiregulin) in tissue remodeling. For example, we assessed the role of clinically relevant growth factors derived from airway epithelial cells in regulating remodeling in our chronic model. 177 At the time, the relationship between growth factor production by the airway epithelium and the subsequent development of remodeling remained poorly understood.
We demonstrated that allergic sensitization increased the biologically active form of TGFβ1 and amphiregulin. 177 Further, regulation of epithelial-derived TGFβ1 was linked to IL-13 production, as TGFβ1 expression was absent in Il13 −/− mice. 177 These studies demonstrated an important role for airway epithelial cell-derived TGFβ1 and potentially other growth factors in the development of airway wall remodeling in chronic asthma.
Further, we assessed the impacts of neutralizing antibody treatment against IL-13, IL-5, and IFNγ in our chronic model. Anti-IL-5 treatment dampened inflammation and remodeling, but had no effect on AHR. 178 Anti-IL-13 also suppressed eosinophil accumulation and partially suppressed airway remodeling, but had limited effects on AHR. 178 Anti-IFNγ treatment suppressed AHR and the accumulation of inflammatory cells, but had no effect on eosinophils or tissue remodeling. 178 In our initial study, we demonstrated that the transfer of OVAspecific polarized T H 1 cells and subsequent challenge with both OVA and LPS were sufficient to induce neutrophil accumulation, macrophage activation and AHR, which was resistant to corticosteroid treatment. 185 Development of AHR was dependent on IFNγ, inhibited by depletion of pulmonary macrophages (but not neutrophils) and abrogated in TLR4-or MyD88-deficient mice. 185 The delivery of IFNγ and LPS (together but not individually) to the lungs also induced steroid-resistant inflammation and AHR. 185 The steroid-resistant pathway operated independently of STAT6. 185 In contrast, transfer of OVA-specific polarized T H 2 cells induced eosinophilia and AHR, which could be suppressed by steroid treatment. 185 This study demonstrated that cooperative signaling between IFNγ and TLR4/MyD88 constitutes a previously unrecognized pathway that regulates macrophagedependent steroid-resistant AHR. This pathway may have an important role in the pathogenesis of airflow obstruction and AHR in asthma that is insensitive or unresponsive to steroid therapy.
To further investigate this novel interaction between IFNγ and LPS, and the mechanism regulating steroid resistance, we performed gene arrays on isolated airway samples after intratracheal administration of IFNγ and/or LPS. We discovered that IL-27 was the most abundantly upregulated transcript that was differentially regulated by combined administration of IFNγ and LPS. 186 Next, we demonstrated that exposure of pulmonary macrophages to IFNγ and LPS also induced IL-27 production. Importantly, integrated signaling by IL-27/IFNγ (but not LPS and IL-27) induced macrophage-dependent steroid-resistant AHR. 186 IL-27/IFNγ administration also blocked glucocorticoidinduced translocation of the glucocorticoid receptor (GR) into the nucleus, in isolated macrophages. 186 Furthermore, expression of both IL-27 and IFNγ was increased in induced sputum samples from steroidrefractory asthma patients. 186 Collectively, our observations suggest that a novel IL-27-and IFNγ-driven pathway may be important in the regulation of steroid-resistant inflammation and AHR and that manipulation of this pathway may be of therapeutic benefit.
Next, we extended these observations into a mouse model of allergen-induced steroid-resistant AHR. In this study, we demonstrated that prolonged AHR was dependent on the presence of IFNγ and macrophages. 187 The source of the IFNγ required for the development of steroid-resistant AHR appears to be resident pulmonary cells, 187 possibly including activated natural killer cells. Significantly, prolonged AHR was independent of eosinophil-dominated pulmonary inflammation and the production of T H 2 cytokines, such as IL-5 and IL-13. 187 These findings further emphasized the contribution of innate host defense pathways to the manifestations of asthma.
| Mechanisms of exacerbation induced by viral infections
Viral infections, the most common being caused by rhinovirus (RV) 188 and RSV, 189, 190 are major triggers of asthma exacerbations (reviewed in [191] [192] [193] ). In very recent studies, we have developed a model of RSVinduced steroid-resistant exacerbation. RSV infection on the background of established AAD (OVA-sensitized/challenged BALB/c mice) resulted in significantly increased macrophage and neutrophil lung infiltration and AHR. 194 Exacerbation was accompanied by increased levels of inflammatory cytokines in the lung, including TNFα, MCP-1/ CCL2, and keratinocyte-derived protein chemokine [KC]/CXCL1. 194 Dexamethasone treatment of RSV-induced exacerbation only partially suppressed AHR and failed to inhibit macrophage and neutrophil infiltration or inflammatory cytokine production. 194 Interestingly, we also observed increased TNFα levels in sputum samples from patients with neutrophilic asthma, 194 a population that is more likely to exhibit steroid-resistant disease. Although RSV-induced exacerbation was resistant to steroid treatment, inhibition of either TNFα or MCP-1/ CCL2 function or depletion of macrophages suppressed features of disease, including AHR and monocyte and neutrophil infiltration. 194 High levels of TNFα have been directly associated with steroid resistance, severe asthma, neutrophilic infiltration, and viral-induced exacerbations. [195] [196] [197] The therapeutic benefit, however, would have to be judged against increased risk of infection, similar to that observed in anti-TNFα studies in humans. 198, 199 In this model, levels of IFNγ and IL-27 were also increased, and again expression of these factors was resistant to steroid therapy (T.H. Collectively, these findings highlight critical roles for macrophages and inflammatory cytokines (including TNFα, MCP-1/CCL2, IL-27, and IFNγ) in viral-induced exacerbations of asthma and suggest that examination of the pathways they regulate may provide insight into therapeutic approaches for disease management.
| Role of miRNAs and transcriptional regulation in steroid resistance
We have also explored a role for miRNAs in regulating pathways that mediate steroid-resistant inflammation and AHR. miR-9 levels were synergistically increased following IFNγ/LPS co-exposure in isolated macrophages and in vivo and were also increased in sputum samples from neutrophilic asthmatics suggesting a role in the mechanism of steroid resistance. 200 Further, miR-9 production decreased the levels of target transcripts, protein phosphatase 2 regulatory subunit B(B56) d isoform (PPP2R5D), reducing PP2A activity, and also inhibited steroid-induced GR nuclear translocation. 200 Antagomirmediated inhibition of miR-9 increased both PP2A activity and GR nuclear translocation in macrophages and restored steroid sensitivity in isolated macrophages and in several mouse models of steroidresistant AHR. 200 Further studies with Hansbro and colleagues have also demonstrated a key role for miR-21 in a number of infectioninduced steroid-resistant AHR models. 201 Steroid-resistant disease was induced by infection with Chlamydia, Haemophilus influenzae, influenza virus, or RSV, on the background of OVA-induced AAD. 201 In each situation, miR-21 was increased and ant-miR-21 treatment could suppress features of disease. 201 Collectively, the above studies highlight the importance of miRNA for the regulation of inflammation and immune responses to infection, relevant to asthma pathogenesis. Targeting these molecules in
asthma is yet to be performed. However, differential expression has been observed in patients with different asthma phenotypes. 202 Thus, analyzing miRNA expression may aid in developing new therapeutic and diagnostic approaches.
We have also targeted transcriptional regulation (by contrast to translational processes) by inhibiting bromodomain and extraterminal motif (BET) proteins during exacerbation. 203 Histone acetylation has been shown to regulate inflammation and may operate in various inflammatory diseases of the lung. 204, 205 Histone acetylation is recognized by BET protein family members, including bromodomains (BRD)-2, BRD3, and BRD4. 206, 207 Treatment with I-BET-762 inhibitor was sufficient to broadly inhibit inflammation and AHR in both our reductionist (IFNγ/LPS administration) and RSV infection-induced exacerbation models. 203 
| Modeling allergen-induced exacerbation on the background of chronic disease
To gain insights into the mechanisms regulating exacerbations, we also developed an acute allergen-induced exacerbation model. 208 We challenged mice with preexisting chronic lesions of asthma with a single, moderate level, dose of OVA. Following allergen challenge, airway inflammation resembling an acute asthma exacerbation was rapidly induced and AHR developed. 208 Notably, AHR was not dependent on eosinophils and it appeared to be related to distal inflammatory lesions. 208 During acute exacerbation of chronic asthma, we also observed steroid-resistant neutrophilic inflammation. 209 Dexamethasone suppressed inflammation associated with eosinophil and T lymphocyte recruitment, but did not prevent neutrophil accumulation or development of AHR. 209 Decreased HDAC2 activity and increased NFκB activity observed after allergen challenge were also not altered by steroid treatment. 209 Further, levels of TNFα, GM-CSF, IL-8, and p21waf were increased and not suppressed by steroids. 209 Levels of lipid peroxidation and protein nitration products were also elevated in the acute exacerbation model. 209 We concluded that impaired nuclear recruitment of HDAC2 could be an important mechanism of steroid resistance of neutrophilic inflammation in exacerbations of asthma. Oxidative stress may contribute to decreased HDAC2 activity. In subsequent studies, we were able to demonstrate that during exacerbations of chronic asthma, alveolar macrophage (AM) and CD4 + T-cell production of proinflammatory molecules (IL-1β, IL-6, CXCL-1, and TNFα) and type-2 cytokines (IL-4, IL-5, and IL-13) were enhanced, respectively. 210 Moreover, we provided evidence that enhanced cytokine expression by AMs may play a critical role in triggering increased expression of cytokines by pulmonary CD4 + T cells. Abbreviations: βc = beta common receptor chain, Ant-126 = antagomir against miR-126, Eo(P) = eosinophil (progenitor), ILC2 = innate lymphoid cell type-2, GM-CSF = granulocyte/macrophage colony-stimulating factor, IL = interleukin, T H 2 = CD4 + T-helper type-2 cell
| CONCLUSION AND FUTURE DIRECTIONS
In conclusion, we have demonstrated that inflammation driven by 
